Lipocine (LPCN) Free Cash Flow (2011 - 2025)
Lipocine's (LPCN) quarterly Free Cash Flow came in at -$3.0 million in Q3 2025, down 5.39% YoY from -$3.2 million in Q3 2024, and down 58.29% on a QoQ basis from -$1.9 million in Q2 2025.
Lipocine (LPCN) Free Cash Flow (2011 - 2025) Analysis & Trends
Lipocine (LPCN) has 15 years of Free Cash Flow data on file, last reported at -$3.0 million in Q3 2025.
- Quarterly Free Cash Flow fell 5.39% year-over-year to -$3.0 million in Q3 2025, while the trailing twelve-month figure through Dec 2025 was -$6.8 million (down 455.63% YoY) and the FY2024 annual result came in at -$1.3 million, up 88.96% from the prior year.
- Free Cash Flow eased to -$3.0 million in Q3 2025, from -$1.9 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $9.0 million in Q4 2021 to a low of -$7.0 million in Q3 2021.
- A 5-year average of -$1.9 million and a median of -$2.6 million in 2023 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2021 — Free Cash Flow soared 344.15% — and 2025, when it slumped 181.8%.
- Tracing LPCN's Free Cash Flow over 5 years: stood at $9.0 million in 2021, then sank by 121.52% to -$1.9 million in 2022, then dropped by 4.95% to -$2.0 million in 2023, then soared by 183.28% to $1.7 million in 2024, then sank by 276.47% to -$3.0 million in 2025.
- The last three Free Cash Flow figures came in at -$3.0 million (Q3 2025), -$1.9 million (Q2 2025), and -$2.0 million (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Lipocine | 11.15 Mn | -12.76 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -2.99 Mn |
| Sep 30, 2025 | -2.99 Mn |
| Jun 30, 2025 | -1.89 Mn |
| Jun 30, 2025 | -1.89 Mn |
| Mar 31, 2025 | -1.97 Mn |
| Mar 31, 2025 | -1.97 Mn |
| Dec 31, 2024 | 1.69 Mn |
| Dec 31, 2024 | 1.69 Mn |
| Sep 30, 2024 | -2.83 Mn |
| Sep 30, 2024 | -2.83 Mn |
| Jun 30, 2024 | -2.50 Mn |
| Jun 30, 2024 | -2.50 Mn |
| Mar 31, 2024 | 2.41 Mn |
| Mar 31, 2024 | 2.41 Mn |
| Dec 31, 2023 | -2.03 Mn |
| Dec 31, 2023 | -2.03 Mn |
| Sep 30, 2023 | -2.61 Mn |
| Sep 30, 2023 | -2.61 Mn |
| Jun 30, 2023 | -3.31 Mn |
| Jun 30, 2023 | -3.31 Mn |